Drug intelligence / Profile preview

CAR-108

Development stage: Preclinical
Lead developer: Topmunnity Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

CAR-108 is a chimeric antigen receptor (CAR) T-cell therapy developed by Topmunnity Therapeutics. It is designed to target and inhibit Programmed death-ligand 1 (PDL1). This immunotherapy is currently in preclinical development for the treatment of neoplasms and specifically for triple-negative breast cancer. The therapy aims to leverage the patient's own immune cells, engineered to recognize and attack cancer cells expressing PDL1, thereby enhancing anti-tumor immune responses.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on CAR-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-108.

Explore the full profile